STAT+: Our biggest burning questions on Trump\u2019s order to bring down drug prices
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
WASHINGTON \u2014 President Trump\u2019s executive order to lower drug prices<\/a> through sweeping, cross-agency action left leaders in the pharmaceutical industry scrambling Monday to make sense of what may be ahead \u2014 and how to respond.<\/p>\n The announcement was long on messaging, but short on details. That may explain why share prices for many pharmaceutical and biotech companies dropped in the hours before the announcement, but gained ground after investors took stock of Trump\u2019s moves<\/a>.<\/p>\n \u201cThis has the feel of a Truth Social post in the form of an executive order,\u201d said Brian Reid of Reid Strategic, a consultant who works with drug companies on pricing and access issues. \u201cIt\u2019s a bully pulpit move. There\u2019s no actual instructions on how to use the law to effectuate this. It\u2019s simply a statement that he wants prices to be lower.\u201d<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n